BioSpace News Archive

Drug Development

ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Trial of Novel Disease-Modifying Genetic Medicine, RCT1100 for the Treatment of Primary Ciliary Dyskinesia

ReCode Therapeutics announced today that the first healthy volunteer participants have been dosed in a Phase 1 clinical trial of RCT1100, a first-in-class, mRNA-based genetic medicine for the treatment of people with primary ciliary dyskinesia (PCD) caused by pathogenic mutations in the DNAI1 gene.

March 15, 2023
·
5 min read
Genetown

Nanite Inc. Receives Up to $2M Investment from CF Foundation to Explore a Novel Method to Deliver Genetic Therapies to the Lung

Nanite Inc. announced today an investment from the Cystic Fibrosis Foundation of up to $2 million to develop gene delivery technology.

March 15, 2023
·
2 min read
Deals

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock today announced that the company granted inducement equity awards covering an aggregate of 26,250 shares of its common stock to 1 newly hired employee, consisting of inducement stock options to purchase an aggregate of 15,000 shares of common stock.

March 15, 2023
·
3 min read
Dxcover to Present New Data on Liquid Biopsy Platform at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Dxcover Limited today announced the upcoming presentation of new data on its liquid biopsy platform at the 2023 American Association for Cancer Research (AACR) Annual Meeting, to be held in Orlando, Florida from April 14-19.

March 15, 2023
·
1 min read
Lone Star Bio

Perspectum Completes $19 Million Second Close of Series C Funding Led by Oppenheimer & Co. Inc. (“Oppenheimer”)

Perspectum has completed the second close of its $55 million Series C funding round.

March 15, 2023
·
3 min read
Business

ImmunoPrecise Antibodies’ Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera Bio

Immunoprecise Antibodies Ltd. today announced that Talem Therapeutics LLC, an independently operating subsidiary of IPA, and Libera Bio S.L., have signed a collaboration agreement to jointly address intracellular targets.

March 15, 2023
·
7 min read
Business

Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023

Dyadic International, Inc. today announced that it will report its financial results for the year ended 2022 and host a corporate update conference call on Wednesday, March 29, 2023.

March 15, 2023
·
3 min read
Business

Standard BioTools Announces Appointment of Fenel Eloi to Board of Directors

Standard BioTools Inc., driven by a bold purpose announced the appointment of Fenel Eloi to its Board of Directors.

March 15, 2023
·
3 min read
Business

Evoke Pharma to Report Fourth Quarter and Full Year 2022 Results on March 21, 2023

Evoke Pharma, Inc. today announced that the Company is scheduled to release its fourth quarter and full year 2022 financial results on Tuesday, March 21, 2023, after the market closes.

March 15, 2023
·
3 min read
Business

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the fiscal year ended December 31, 2022, and provided a corporate update.

March 15, 2023
·
13 min read